LFCR

Handel nachbörslich: 4.20

Lifecore Biomedical Inc (LFCR)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Lifecore Biomedical Inc Stock (LFCR) Company Profile

Lifecore Biomedical Inc

Healthcare (1067)

(952) 368-4300

3515 LYMAN BOULEVARD, CHASKA

Nächster Verdiensttermin

Neueste SEC-Einreichungen

LFCR's Discussions on Twitter

Compare LFCR vs TAK, TEVA, HLN, ZTS, VTRS

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LFCR Lifecore Biomedical Inc	4.20	158.98M	147.12M	-33.88M	-13.62M	-0.4805
TAK Takeda Pharmaceutical Co Adr	18.86	60.23B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	39.19	45.71B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.26	40.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	71.05	29.36B	9.51B	2.64B	2.14B	6.0361
VTRS Viatris Inc	17.83	20.48B	14.57B	-296.50M	1.64B	-0.259

Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-17	Hochstufung	Barrington Research	Mkt Perform → Outperform
2025-09-04	Eingeleitet	KeyBanc Capital Markets	Sector Weight
2025-05-21	Eingeleitet	William Blair	Outperform
2024-09-05	Eingeleitet	Craig Hallum	Buy
2024-08-28	Herabstufung	Barrington Research	Outperform → Mkt Perform
2023-03-20	Herabstufung	Stephens	Overweight → Equal-Weight

Alle ansehen

Lifecore Biomedical Inc Aktie (LFCR) Neueste Nachrichten

Finanzdaten der Lifecore Biomedical Inc-Aktie (LFCR)

Lifecore Biomedical Inc (LFCR)

Lifecore Biomedical Inc Stock (LFCR) Company Profile

Compare LFCR vs TAK, TEVA, HLN, ZTS, VTRS

Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades

Lifecore Biomedical Inc Aktie (LFCR) Neueste Nachrichten

Lifecore Biomedical, Inc. (LFCR) Stock Price Prediction for 2026, 2030-2040 - Traders Union

Lifecore Biomedical: A Messy Balance Sheet, A Much Better Business (NASDAQ:LFCR) - Seeking Alpha

Lifecore plans customer meetings in Milan this October - Stock Titan

Lifecore Biomedical to Participate at CPHI Global Conference - GlobeNewswire

Lifecore Strikes Tech Transfer Deal for Commercial Manufacturing of Major Pharma Company Injectable - Contract Pharma

Lifecore Biomedical Signs New Commercial Transfer Agreement for Marketed Injectable Product - Quiver Quantitative

A marketed injectable drug is expected to bring Lifecore revenue in 2028. - Stock Titan

LFCR Q2 2026 Earnings: Narrower Loss of -$0.19 Beats Estimates, Shares Dip 1.35%Revenue Guidance Update - vinanet.vn

Lifecore (LFCR) Results at a Glance: EPS Lands Above Forecast in Latest Trading; Session Move: Shares Rise 0.22% at the CloseEarnings Season Preview - vinanet.vn

Lifecore (LFCR) Earnings Reading: EPS Prints Above Forecast at the Close; After Results: Shares Move 2.42% Down on the DayGuidance Downgrade Alert - vinanet.vn

LFCR | Lifecore Biomedical, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative

Lifecore Biomedical Earnings Call Balances Growth and Strain - TipRanks

Lifecore (LFCR) Quarterly Scorecard: EPS Beats Its Estimate; The Stock Records a 1.83% Increase on the DayROA Comparison - vinanet.vn

Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript - AOL.com

Core Thesis Behind Lifecore Biomedical (LFCR): Monetizing Excess Capacity - Yahoo Finance

Avoiding Lag: Real-Time Signals in (LFCR) Movement - news.stocktradersdaily.com

LFCR Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 16.59% EPS SurpriseAnalyst Coverage Count - vinanet.vn

Lifecore Biomedical (LFCR) Holds Above $4.50 Support as Shares Edge LowerSell Signal Alerts - vinanet.vn

LFCR Q2 2026 Earnings: Narrower-than-Expected Loss Offers Modest EncouragementGuidance vs Actual - vinanet.vn

Judge approves $3.75 million Lifecore investor settlement - Minnesota Lawyer

William Blair Maintains Lifecore Biomedical(LFCR.US) With Buy Rating - Moomoo

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update - marketscreener.com

Lifecore Biomedical, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Discipline and Rules-Based Execution in LFCR Response - Stock Traders Daily

Earnings call transcript: Lifecore Biomedical tops revenue view in Q2 2026 - Investing.com Canada

Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat

Transcript : Lifecore Biomedical, Inc., Q2 2026 Earnings Call, Aug 05, 2026 - marketscreener.com

Lifecore Biomedical, Inc. Reaffirms Earnings Guidance for the Calendar Year 2026 - marketscreener.com

LFCR: Revenue and profit declined, but cost cuts and new wins support strong long-term growth outlook - TradingView

Lifecore Biomedical, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Lifecore Biomedical Q2 Earnings Call Highlights - MarketBeat

Lifecore Biomedical, Inc. (LFCR) Q2 FY2026 earnings call transcript - Yahoo Finance

LFCR: Q2 revenue fell 6.2% to $34.2M, but new business wins and guidance reaffirmed - tradingview.com

Lifecore Biomedical Backs 2026 Adj EBITDA of $20.5M-$25M >LFCR - Moomoo

Lifecore Biomedical Q2 revenue falls to $34.2 million as loss widens - Quiver Quantitative

Lifecore Biomedical 2026: Revenue $34.17M, EPS ($0.19) — 10-Q Summary - TradingView

Lifecore Biomedical: Q2 Earnings Snapshot - marketscreener.com

Lifecore Biomedical (NASDAQ: LFCR) Q2 revenue slips as 2026 guidance reaffirmed - Stock Titan

Lifecore Biomedical Reports Financial Results for the - GlobeNewswire

LFCR: Q2 2026 delivered strong revenue, margin expansion, and robust pipeline growth - TradingView

Lifecore Biomedical Q2 FY26 net loss widens to $6.2 million; revenue falls 6.2% to $34.2 million - Bitget

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile

Lifecore Biomedical Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile

LFCR Q1 2026 Earnings: Wider-than-Expected Loss Overshadows the QuarterEstimate Dispersion - careplusvn.com

Zacks Research Upgrades Lifecore Biomedical (NASDAQ:LFCR) to Hold - MarketBeat

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026 - GlobeNewswire

LFCR Q1 2026 Earnings: Significant Earnings Miss Amid Operational ChallengesAnalyst Earnings Estimate - careplusvn.com

Lifecore Biomedical (LFCR) Tests Resistance After a Modest UptickBull Flag - dars.gov.et

Finanzdaten der Lifecore Biomedical Inc-Aktie (LFCR)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie LFCR